-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Merck (MRK)
-
-
-
-
-
-
-
Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent
-
-
-
-
-
-
-
Wells lists 14 high-conviction long ideas for Q1 2026
-
-
-
-
-
-
-
Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30
-
-
-
-
-
-
-
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
-
-
-
-
-
-
-
Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24
-
-
-
-
-
-
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
-
1,204,157 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

